Karolinska Institutet and Affymetrix Announce Translational Medicine Strategic Alliance
Researchers at Karolinska Institutet will undertake large-scale clinical studies with the goal of translating basic research into tools for better treatment.
Affymetrix Inc. and Karolinska Institutet announced that they have entered into a strategic alliance designed to improve healthcare by accelerating the translation of basic genetic research into tools for better diagnosis, prognosis, and treatment.
During the next five years the projects include genetic analyses and measurement of gene expression in patients with atherosclerosis, breast cancer, rheumatoid arthritis, asthma and dyslexia. These diseases affect a large number of patients worldwide. Systematic use of the genomic information obtained will enable development of new and better clinical methods and drugs hereby reducing mortality and improving quality of life for patients suffering from these diseases.
The Karolinska Institutet/Affymetrix Translational medicine research projects will use sufficiently large sample sizes to establish true clinical relevance of both gene expression and DNA sequence variation in key areas of unmet medical needs.
Karolinska Institutet agreement is part of the Affymetrix Translational Medicine Initiative. The goal of the initiative is to bridge the gap between clinical research and application of genomics in patient care by bringing together leading clinical research institutes with advanced Affymetrix microarray technology.
Other news from the department science
